Added to YB: 2026-06-11
Pitch date: 2026-06-09
LLY [bullish]
Eli Lilly and Company
-1.4%
current return
Author Info
FluentInQuality invests in high-quality businesses that generate steady and sustainable cashflows, proven track records, and the potential to act as a true compounding machines over the long run. Sign up for the newsletter.
Company Info
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
Market Cap
$1.0T
Pitch Price
$1.2K
Price Target
N/A
Dividend
0.60%
EV/EBITDA
29.06
P/E
40.66
EV/Sales
14.65
Sector
Pharmaceuticals
Category
growth
Eli Lilly Is Up 32% in Six Weeks. Here Is Exactly Why the Market Is Not Wrong.
LLY: Q1'26 rev +56% YoY, EPS $8.55 (+156%); FY26 guide raised to $82-85B rev, $35.50-37 EPS, 47-48.5% op margin. Mounjaro/Zepbound $12.8B/qtr. New oral pill Foundayo (orforglipron) launched, 80% naive patients, scalable small-molecule edge vs Novo. Retatrutide Phase 3: 85lb loss. +32% in 6wks; catalysts (Q3 ads, Medicare, intl) still ahead.
Read full article (11 min)